Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Apr 29, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on developing a new prediction model to better understand how VHL syndrome affects kidney cancer, specifically renal cell carcinoma (RCC). VHL syndrome is a rare condition that can lead to the development of tumors, and RCC is one of the most serious complications, often requiring multiple surgeries over a patient's lifetime. The goal of the trial is to identify the best times for surgery and reduce the number of operations needed, ultimately improving the health outcomes for patients with VHL syndrome.

To participate in this study, individuals must have a confirmed diagnosis of VHL syndrome and have undergone various medical assessments, including imaging tests of different organs. Participants should also have had any kidney tumor surgeries at least a year prior to joining the trial. Throughout the study, participants will be monitored closely to gather information that can help in the accurate diagnosis and treatment of VHL-related kidney cancer. This trial is currently recruiting and is open to individuals of all genders aged 18 and older.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of VHL syndrome based on clinical diagnostic criteria or genetic test results of syndrome
• • Upon enrollment, multiple organ assessments for VHL syndrome should be completed, including fundus examination, CT/MR examination of the brain, spinal cord, and abdominal and pelvic organs.
• • If subjects have undergone surgery for renal tumors, the follow-up observation time in each branch center before surgery should be more than 12 months, and imaging examinations should be performed at least once every 6 months.
• Exclusion Criteria:
• • Do not meet the clinical diagnostic criteria for VHL disease or the genetic test is negative
• • Other hereditary RCC syndromes